stethoscope

Join our network and find credentialing information.

Log in to Availity Essentials™ to access patient benefits, claims information and more.

Find tools and materials to support doing business with us.

Learn more about research and trends that impact your practice.

Find self-service info and phone numbers and update your provider data.

Review prior authorization lists for services, medications and submission guidance.

Prior authorization submission information

Professionally administered drugs prior authorization

Find appeals guidelines and payment policy information.

Learn how to submit claims and find coding guidance.

Find policies for procedures, devices and medications.

Review guidelines and health programs to support your patients and practice.

Find dental benefits, tools and resources.

Prior authorization for professionally administered drugs 

Locate state-specific resources for Humana Healthy Horizons® (Medicaid).

compass

Shop plans, learn about Medicare and explore member resources.

Search for in-network medical, vision, dental and pharmacy providers.

Pharmacy news

A woman reads information about her precription drugs on her tablet

Drug recall notice for fentanyl transdermal system 

A couple researching a prescription online

Drug recall notice for Prograf and Astagraf XL capsules

Drug recall notice for clonazepam orally disintegrating tablets

For a list of pharmacy news bulletins, pharmacists may sign in to the Pharmacist Portal. If you do not have access, you can register for a new account.

The Inflation Reduction Act (IRA) became law on August 16, 2022 and includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government

Learn more about the IRA

Notifications and prior authorizations

PD-1/PD-L1 non-small cell lung cancer update for 2025 for Humana Medicare Advantage members

Continuous glucose monitors available at pharmacy in 2024


GLP-1 medically accepted indication update

Formulary changes for generic Ventolin HFA

Formulary changes for generic Zytiga

Drug recalls

Drug withdrawal notice for Oxbryta 


Drug recall notice for atovaquone oral suspension


Drug recall notice for potassium chloride 750 mg extended-release capsules (Glenmark Pharmaceuticals)

Drug recall notice for potassium chloride 750 mg extended-release capsules (BluePoint Laboratories)

Drug recall notice for clonazepam orally disintegrating tablets

Market withdrawal of Relyvrio

Drug recall notice for all Akorn drug products


Market withdrawal of Makena (hydroxyprogesterone caproate injection)


Drug recall notice for quinapril products

Drug recall notice for quinapril and hydrochlorothiazide tablets

Market withdrawal of Ukoniq tablets

Drug recall notice for orphenadrine citrate tablets

Drug recall notice for Symjepi (epinephrine) injection

Drug recall notice for Hizentra 20% (10 g/50 mL)

Drug recall notice for irbesartan tablets

Drug recall notice for Glucagon Emergency Kit

Drug recall notice for Lotrimin AF and Tinactin spray products

Drug recall notice for Ruzurgi (amifampridine) 10 mg tablets

Drug recall notice for Chantix (varenicline) tablets

Drug recall notice for NP Thyroid tablets

Drug recall notice for metformin extended-release products

Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

Drug recall notice for nizatidine capsules

Market withdrawal of all ranitidine products

Drug recall notice for Natpara

Impact of ongoing angiotensin II receptor blocker drug recalls

Additional notifications

Information about generic Namzaric

Effective Jan. 18, 2025, generic Namzaric (memantine HCl and donepezil HCl) is not covered on Humana’s Medicare Advantage prescription drug plans. Brand-name Namzaric will continue to be covered and can be filled for your patients.  

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time. 

Generic Namzaric FAQ

An important update regarding prescription drug coverage for Lagevrio (molnupiravir)

Emergency Use Authorization (EUA)-labeled Lagevrio™ (molnupiravir) was removed from Humana’s formulary on Jan. 1, 2025, because it no longer meets the definition of a Medicare Part D drug, effective April 1, 2025.

Paxlovid™ (nirmatrelvir tablets, ritonavir tablets) will remain covered on Humana’s formulary as an oral antiviral for the treatment of COVID-19.

You can submit a request for Humana to make an exception by calling Humana Clinical Pharmacy Review at 800-555-CLIN (2546) (TTY: 711), Monday – Friday, 8 a.m. – 6 p.m., Eastern time. For prescription drug coverage requests in Puerto Rico, please call 866-773-5959 (TTY: 711), Monday – Friday, 8 a.m. – 8 p.m., Eastern time.

Information about generic Advair HFA

Effective Jan. 1, 2025, generic Advair HFA (fluticasone/salmeterol) is not covered on Humana’s Medicare Advantage prescription drug plans. Brand-name Advair HFA will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call  800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time. 

Generic Advair HFA FAQ

Information about generic Combigan

Effective Jan. 1, 2025, generic Combigan (brimonidine-timolol) is not covered on Humana’s Medicare Advantage prescription drug plans. Brand-name Combigan will continue to be covered and can be filled for your patients. 

Prescribers with questions regarding this change can call 800-555-CLIN (555-2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time.

Generic Combigan FAQ

Information about generic Symbicort HFA inhaler

Effective Jan. 1, 2025, generic Symbicort HFA inhaler (budesonide/formoterol inhaler) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Symbicort HFA inhaler will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (555-2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time.

Generic Symbicort HFA inhaler FAQ

An important update regarding prescription drug coverage for HIV PrEP

Currently, antiretroviral drugs used for the prevention of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) are covered under Medicare Part D. To assist you in the care of your patients, we are notifying you that HIV PrEP drugs (Apretude, cabotegravir, Descovy®, emtricitabine and tenofovir disoproxil fumarate, and Truvada®) may be covered under Medicare Part B for prevention of pre-exposure, effective late September 2024. However, if these prescription drugs are used to treat HIV, they will remain covered under Medicare Part D. This change is occurring in response to a proposed National Coverage Determination from the Centers for Medicare & Medicaid Services. 

If your patients have their Medicare Part B benefit covered with a different health plan, they may need to inform their pharmacy to use that plan for coverage when these prescription drugs are being administered for pre-exposure prevention.

You can submit a request for Humana to make an exception by calling Humana Clinical Pharmacy Review at 800-555-CLIN (2546) (TTY:711), Monday – Friday, 8 a.m. – 6 p.m., Eastern time. For prescription drug coverage requests in Puerto Rico, please call 866-773-5959.

Information about the launch of generic Myrbetriq

Effective on the date of launch, April 27, 2024, generic Myrbetriq (mirabegron) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Myrbetriq will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Myrbetriq FAQ,

An important update regarding prescription drug coverage for tropicamide eye drops

To assist you in the care of your patients, we are notifying you that tropicamide eye drops will be removed from Humana’s formulary on July 15, 2024. Humana has determined that tropicamide eye drops are no longer eligible for Medicare Part D prescription drug coverage.

Sufficient clinical alternatives may not be available on Humana’s formulary, but we encourage you to use Humana’s Drug List formulary search tool on the Humana Drug Lists provider website. This tool can help you review appropriate alternatives that are available on Humana’s formulary.

You also can submit a request for Humana to make an exception by calling Humana Clinical Pharmacy Review at 800-555-CLIN (2546) (TTY:711), Monday – Friday, 8 a.m. – 6 p.m., Eastern time. For drug coverage requests in Puerto Rico, please call 866-773-5959.

We have sent a letter to your Humana-covered patients who have had a claim for tropicamide eye drops to inform them of this midyear formulary change and encourage them to work with their healthcare provider on alternative options.

Information about the launch of generic Farxiga

Effective on the date of launch, Jan. 6, 2024, generic Farxiga (dapagliflozin) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Farxiga will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Farxiga FAQ

Information about the launch of generic Xigduo XR

Effective on the date of launch, Jan. 6, 2024, generic Xigduo XR (dapagliflozin-metformin) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Xigduo XR will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Xigduo XR FAQ

Information about the launch of generic Risperdal Consta

Effective on the date of launch, Dec. 16, 2023, generic Risperdal Consta (risperidone extended release) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Risperdal Consta will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Risperdal Consta FAQ

Information about the launch of generic Forteo

Effective on the date of launch, Nov. 25, 2023, generic Forteo (teriparatide) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Forteo will continue to be covered with prior authorization and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Forteo FAQ

Information about the launch of generic Breo Ellipta

Effective on the date of launch, Jan. 1, 2024, generic Breo Ellipta (fluticasone furoate/vilanterol) is not covered on Humana’s commercial formularies, Medicare Advantage prescription drug plans and Medicare Part D plans. Brand-name Breo Ellipta will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Breo Ellipta FAQ

Information about the launch of generic Spiriva with HandiHaler

Effective on the date of launch, Jan. 1, 2024, generic Spiriva with HandiHaler (tiotropium bromide) is not covered or may require step therapy through the brand on Humana’s commercial formularies, Medicare Advantage prescription drug plans and Medicare Part D plans. Brand-name Spiriva with HandiHaler will continue to be covered and can be filled for your patients.

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Spiriva with HandiHaler FAQ

Information about the launch of generic Vascepa

Effective Jan. 1, 2023, generic Vascepa (icosapent) is not covered or may require step therapy on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Vascepa will continue to be covered and can be filled for patients.

Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Vascepa FAQ

Formulary changes for Revlimid

Lenalidomide, the generic version of Revlimid®, is covered by Humana with a prior authorization and will remain covered in 2023. Effective Jan. 1, 2023, Humana Medicare plans will no longer cover Revlimid. If the generic version is not available at your patient’s pharmacy, please include this information in your coverage exception request. We have notified your patients who had a claim for Revlimid in 2022 about this formulary change.

Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Updates could mean new requirements for Humana members

Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.

These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.

Information about the launch of generic Durezol

Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Durezol FAQ

Point-of-sale edits for hydroxychloroquine and chloroquine – effective 7/1/20

Information about the launch of authorized generic insulin aspart and insulin aspart mix

Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Authorized generic insulin aspart and insulin aspart mix FAQ

Med-Edit update notification

As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.

Med-Edit Notification

Drug recall

Drug recall

Drug recall

Pharmacy news bulletins available on the portal